Compare Medpace Holdings Inc (MEDP) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Prospect Capital Corporation — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Prospect Capital Corporation trades at $1.75 (market cap $974.22M). The key difference: Medpace Holdings Inc is far larger — about 17.3× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Prospect Capital Corporation for 78 Days on average.
| MEDP | PSEC | |
|---|---|---|
Market Cap | $16.82B | $974.22M |
Volume | 223,093 | 5,779,996 |
Sector | Health | Financials |
52-Week High | $630.19 | $3.05 |
52-Week Low | $393.42 | $1.82 |
Typical Hold Time | 14 Days | 78 Days |
Enterprise Value | $16.44B | $2.73B |
Dividend Yield | — | 23.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
PSEC trades at $1.72, down 6.52% today, amid bearish technical signals and mixed fundamentals. The stock shows consistent earnings beats but faces revenue volatility with negative 2025 results. Recent news highlights dividend distributions and portfolio management activity, while analysts remain cautious with 55% hold ratings. Technical indicators show oversold conditions with RSI below 10, but moving averages signal continued downward pressure.
PSEC presents a high-risk opportunity with an 18%+ yield and deep NAV discount, but faces significant headwinds from portfolio contraction and declining investment income. The dividend cut to $0.035 improves coverage, yet persistent NAV erosion and bearish analyst sentiment suggest limited near-term upside. Investors should weigh the attractive yield against fundamental deterioration and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
